Table 2.
Symptom Scores by Week and Treatment Group
| Week | Rasagiline Mean (±SD) | Placebo Mean (±SD) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| N | SANS Total Score | BPRS Total Score | BPRS Positive Symptom Item Score | CDS Total Score | N | SANS Total Score | BPRS Total Score | BPRS Positive Symptom Item Score | CDS Total Score | |
| 0 | 26 | 32.7 (8.5) | 33.7 (6.9) | 8.8 (3.2) | 2.3 (2.1) | 28 | 33.5 (7.8) | 33.3 (6.4) | 9.1 (4.0) | 2.0 (2.4) |
| 4 | 26 | 31.2 (9.4) | 33.9 (7.7) | 9.2 (3.7) | 2.2 (2.1) | 28 | 32.3 (8.2) | 32.3 (6.7) | 9.4 (3.9) | 2.0 (2.3) |
| 8 | 26 | 31.1 (8.1) | 33.7 (7.3) | 9.2 (3.5) | 2.3 (1.9) | 25 | 34.1 (8.6) | 33.3 (6.5) | 9.8 (4.2) | 1.5 (1.9) |
| 12 | 26 | 29.9 (9.3) | 33.2 (6.9) | 8.3 (3.3) | 2.6 (2.6) | 23 | 34.3 (8.6) | 31.8 (6.9) | 8.9 (3.7) | 1.5 (2.2) |
| Week 12 change from baseline | 26 | −2.8 (5.8) | −0.5 (6.4) | −0.5 (2.4) | 0.3 (2.1) | 23 | 0.6 (4.2) | -0.8 (3.1) | 0.0 (1.8) | 0.0 (1.6) |
Note: Abbreviations are explained in the first footnote to table 1. In the mixed model analysis of covariance, with time treated as a continuous variable, there was a significant treatment × time interaction for SANS total score (F(1,40.3) = 5.61, P = .023), but not for BPRS total score (F(1,44.9) = 1.15, P = .29), BPRS positive symptom item score (F(1,48.2) = 2.73, P = .10), or CDS total score (F(1,44.8) = 0.37, P = .54).